Wednesday, 28 September 2011

FDA Studies Show High Risk of Blood Clots with Yaz and Yasmin

Preliminary studies by the Food and Drug Administration seem to confirm a high risk of blood clots in women who use Yaz, Yasmin and other new generation contraceptive pills. According to the data, these women have a 1½ times higher risk of developing blood clots, compared to women who use other, older contraceptive pills.

The FDA study involved 500,000 women in the United States, and the results have been posted on the agency's website. According to the agency, it does not yet have enough data to conclude firmly that new generation birth-control pills like Yaz and Yasmin are definitely linked to an increased risk of developing blood clots. For now, all that the agency will say is that it is concerned about the increased potential for developing blood clots in women who use pills like Yaz and Yasmin that contain drospirenone.

Both Yasmin and Yaz are manufactured by Bayer Healthcare Pharmaceuticals, and both contain ethinyl estradiol. These new generation pills quickly became very popular among women, because of their ability to treat acne, prevent symptoms of premenstrual dysphoric disorder, and avoid unwanted pregnancies. However, Los Angeles personal injury attorneys have also been concerned about the increasing number of complaints associating Yaz and Yasmin use with a number of life-threatening side effects. These side effects include pulmonary embolism, life-threatening blood clots, strokes and heart attacks.

Bayer faces dozens of personal injury lawsuits filed by women who suffered blood clots from Yaz and Yasmin use. Many of these injuries have also occurred because the drugs are prescribed to teenagers to treat conditions like acne or premenstrual syndrome. The Food and Drug Administration has said that it will meet with two advisory panels later in the year to sift through data about these two pills, from several studies that have been conducted in the past.